U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Ovarian Carcinoma

MedGen UID:
1651209
•Concept ID:
C4725612
•
Neoplastic Process

Definition

Ovarian carcinoma that is resistant to treatment. [from NCI]

Professional guidelines

PubMed

Intraperitoneal therapy in the management of ovarian carcinoma.
Markman M, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadones L, Lewis JL Jr
Yale J Biol Med 1989 Jul-Aug;62(4):393-403. PMID: 2688324Free PMC Article
Intraperitoneal cisplatin chemotherapy in the management of ovarian carcinoma.
Markman M
Semin Oncol 1989 Aug;16(4 Suppl 6):79-82. PMID: 2669140
Treatment of advanced refractory ovarian carcinoma with a gonadotropin-releasing hormone analogue.
Bruckner HW, Motwani BT
Am J Obstet Gynecol 1989 Nov;161(5):1216-8. doi: 10.1016/0002-9378(89)90669-8. PMID: 2511761

Recent clinical studies

Etiology

Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: A single-center retrospective study.
Chen W, Li Z, Zheng Z, Wu X
Cancer Med 2020 Aug;9(16):5899-5907. Epub 2020 Jul 6 doi: 10.1002/cam4.3282. PMID: 32627959Free PMC Article
Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.
Fracasso PM, Brady MF, Moore DH, Walker JL, Rose PG, Letvak L, Grogan TM, McGuire WP
J Clin Oncol 2001 Jun 15;19(12):2975-82. doi: 10.1200/JCO.2001.19.12.2975. PMID: 11408492
Treatment of refractory ovarian carcinoma with paclitaxel and cisplatin after treatment failure with single-agent paclitaxel.
Johnston CM, Pearl ML, Reynolds RK, Roberts JA, Morley GW
Eur J Gynaecol Oncol 1995;16(6):439-47. PMID: 8536758
A phase II trial of high-dose mitoxantrone, carboplatin, and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: analysis of risk factors for clinical outcome.
Stiff P, Bayer R, Camarda M, Tan S, Dolan J, Potkul R, Loutfi S, Kinch L, Sosman J, Peace D
Gynecol Oncol 1995 Jun;57(3):278-85. doi: 10.1006/gyno.1995.1143. PMID: 7774830
Salvage therapy in epithelial ovarian cancer.
Caldas C, Morris LE, McGuire WP 3rd
Obstet Gynecol Clin North Am 1994 Mar;21(1):179-94. PMID: 8015763

Diagnosis

Inflammatory skin metastases from ovarian carcinoma--a case report and review of the literature.
Schonmann R, Altaras M, Biron T, Bernheim J, Fishman A
Gynecol Oncol 2003 Sep;90(3):670-2. doi: 10.1016/s0090-8258(03)00366-4. PMID: 13678744
In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M, Zunino F
Cancer Chemother Pharmacol 1998;41(5):385-90. doi: 10.1007/s002800050755. PMID: 9523734
A phase II trial of high-dose mitoxantrone, carboplatin, and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: analysis of risk factors for clinical outcome.
Stiff P, Bayer R, Camarda M, Tan S, Dolan J, Potkul R, Loutfi S, Kinch L, Sosman J, Peace D
Gynecol Oncol 1995 Jun;57(3):278-85. doi: 10.1006/gyno.1995.1143. PMID: 7774830
Paclitaxel (Taxol): a novel anticancer chemotherapeutic drug.
Long HJ
Mayo Clin Proc 1994 Apr;69(4):341-5. doi: 10.1016/s0025-6196(12)62219-8. PMID: 7909575
Phase II trial of thio-TEPA in relapsed and refractory ovarian carcinoma.
Langer CJ, Nash S, Catalano R, Rosenblum NG, Hogan WM, Comis RL, O'Dwyer PJ
Gynecol Oncol 1991 Dec;43(3):242-6. doi: 10.1016/0090-8258(91)90028-4. PMID: 1752494

Therapy

Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: A single-center retrospective study.
Chen W, Li Z, Zheng Z, Wu X
Cancer Med 2020 Aug;9(16):5899-5907. Epub 2020 Jul 6 doi: 10.1002/cam4.3282. PMID: 32627959Free PMC Article
Paclitaxel efficacy and tolerability in second-line treatment of refractory and relapsed ovarian cancer patients.
Oliverio G, Canuti D, Tononi A, Scarpellini M, Panzini I, Galli I, Ravaioli A
J Chemother 1999 Aug;11(4):301-5. doi: 10.1179/joc.1999.11.4.301. PMID: 10465133
In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M, Zunino F
Cancer Chemother Pharmacol 1998;41(5):385-90. doi: 10.1007/s002800050755. PMID: 9523734
Paclitaxel (Taxol): a novel anticancer chemotherapeutic drug.
Long HJ
Mayo Clin Proc 1994 Apr;69(4):341-5. doi: 10.1016/s0025-6196(12)62219-8. PMID: 7909575
Intraperitoneal therapy in the management of ovarian carcinoma.
Markman M, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadones L, Lewis JL Jr
Yale J Biol Med 1989 Jul-Aug;62(4):393-403. PMID: 2688324Free PMC Article

Prognosis

Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.
Fracasso PM, Brady MF, Moore DH, Walker JL, Rose PG, Letvak L, Grogan TM, McGuire WP
J Clin Oncol 2001 Jun 15;19(12):2975-82. doi: 10.1200/JCO.2001.19.12.2975. PMID: 11408492
Treatment of refractory ovarian carcinoma with paclitaxel and cisplatin after treatment failure with single-agent paclitaxel.
Johnston CM, Pearl ML, Reynolds RK, Roberts JA, Morley GW
Eur J Gynaecol Oncol 1995;16(6):439-47. PMID: 8536758
A phase II trial of high-dose mitoxantrone, carboplatin, and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: analysis of risk factors for clinical outcome.
Stiff P, Bayer R, Camarda M, Tan S, Dolan J, Potkul R, Loutfi S, Kinch L, Sosman J, Peace D
Gynecol Oncol 1995 Jun;57(3):278-85. doi: 10.1006/gyno.1995.1143. PMID: 7774830
Salvage therapy in epithelial ovarian cancer.
Caldas C, Morris LE, McGuire WP 3rd
Obstet Gynecol Clin North Am 1994 Mar;21(1):179-94. PMID: 8015763
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH
J Clin Oncol 1992 Apr;10(4):647-56. doi: 10.1200/JCO.1992.10.4.647. PMID: 1312588

Clinical prediction guides

Gemcitabine and anthracyclines in platinum-resistant ovarian cancer.
Galligioni E, Arcuri C, Sorio R, Griso C
Ann Oncol 2006 May;17 Suppl 5:v195-8. doi: 10.1093/annonc/mdj980. PMID: 16807455
Paclitaxel efficacy and tolerability in second-line treatment of refractory and relapsed ovarian cancer patients.
Oliverio G, Canuti D, Tononi A, Scarpellini M, Panzini I, Galli I, Ravaioli A
J Chemother 1999 Aug;11(4):301-5. doi: 10.1179/joc.1999.11.4.301. PMID: 10465133
In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M, Zunino F
Cancer Chemother Pharmacol 1998;41(5):385-90. doi: 10.1007/s002800050755. PMID: 9523734
Increased thymidine kinase and thymidylate synthase activities in human epithelial ovarian carcinoma.
Look KY, Moore DH, Sutton GP, Prajda N, Abonyi M, Weber G
Anticancer Res 1997 Jul-Aug;17(4A):2353-6. PMID: 9252646
Intraperitoneal therapy in the management of ovarian carcinoma.
Markman M, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadones L, Lewis JL Jr
Yale J Biol Med 1989 Jul-Aug;62(4):393-403. PMID: 2688324Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...